Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Others

Ratios

Immunovant (IMVT) Other financing activities (2019 - 2026)

Immunovant filings provide 3 years of Other financing activities readings, the most recent being $319000.0 for Q1 2025.

Quarterly Other financing activities changed N/A to $319000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $319000.0 through Mar 2025, changed N/A year-over-year, with the annual reading at $319000.0 for FY2025, 94.69% down from the prior year.
Other financing activities hit $319000.0 in Q1 2025 for Immunovant, up from $261000.0 in the prior quarter.
Across five years, Other financing activities topped out at $319000.0 in Q1 2025 and bottomed at $319000.0 in Q1 2025.